Welcome to EQUITY DEVELOPMENT
The UK's longest established regulated provider of sponsored equity research.
We launched EQUITY DEVELOPMENT in 1997 becoming the first ever regulated provider of Sponsored Equity Research in the UK.
Our research teams are made up of expert analysts with deep understanding & experience in their sectors. Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).
We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.
Search for Company Research
FREE REGISTRATION
Sign up today and access the very latest company research
LOG IN
For access to all company research please
ValiRx
ValiRx is a virtual, emerging biopharmaceutical company focused on the discovery and development of epigenomics technology platforms for the treatment and diagnosis of cancer
Full year results in line with prior expectations
Successful equity placings
Expanded patent estate
Progression of the cancer therapeutic pipeline
Optional in-licensing deal
Fair value / share seen at 21.9p, still materially above current level (6p)
Publication Date:
August 5 2008
GeneICE in vitro studies successfully completed
Collaboration agreement in place with Physiomics
Morphogenesis developing cell separation device
New Chairman appointed
Fair value (unchanged) seen at 33p / share versus current 10p
Publication Date:
January 25 2008
Pursuit of Cancer diagnosis and treatment
Two compounds in advanced pre-clinical trials
A number of research collaboration agreements
Profitability seen in 2009, discounted PER valuation seen well above current price
Publication Date:
October 1 2007